Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary-Reference-Cited by-同舟云学术

Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary

Published:2020-06 Issue:11 Volume:146 Page:3053-3064
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Bochtler Tilmann¹²³⁴^ORCID,Reiling Anna¹⁴,Endris Volker⁵⁶^ORCID,Hielscher Thomas⁷,Volckmar Anna‐Lena⁵,Neumann Olaf⁵,Kirchner Martina⁵,Budczies Jan⁵^ORCID,Heukamp Lukas C.⁸,Leichsenring Jonas⁵,Allgäuer Michael⁵,Kazdal Daniel⁵^ORCID,Löffler Harald¹⁹,Weichert Wilko⁵⁶¹⁰,Schirmacher Peter⁵,Stenzinger Albrecht⁵⁶^ORCID,Krämer Alwin¹⁴

Affiliation:

1. Clinical Cooperation Unit Molecular Hematology/OncologyGerman Cancer Research Center (DKFZ) and Department of Internal Medicine V, University Hospital Heidelberg Heidelberg Germany

2. Department of Thoracic OncologyThoraxklinik Heidelberg Heidelberg Germany

3. Translational Lung Research Center Heidelberg (TLRC‐H), Member of the German Center for Lung Research (DZL) Germany

4. Department of Internal Medicine VUniversity Hospital Heidelberg Heidelberg Germany

5. Institute of Pathology, University Hospital Heidelberg Heidelberg Germany

6. German Cancer Consortium (DKTK) Germany

7. Division of BiostatisticsGerman Cancer Research Center (DKFZ) Heidelberg Germany

8. Institute for Haematopathology Hamburg Hamburg Germany

9. Marienhospital Stuttgart Stuttgart Germany

10. Institute of Pathology, Technical University Munich Munich Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32882

Reference43 articles.

1. Metastases in the absence of a primary tumor: advances in the diagnosis and treatment of CUP syndrome;Neben K;Dtsch Arztebl Int,2008

2. Carcinomas of an unknown primary origin—diagnosis and treatment

3. Cancer of Unknown Primary Site

4. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer of unknown primary—histological and molecular–pathological principles in the diagnostic workup;Die Onkologie;2024-01-15

2. Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary;Clinical Chemistry;2024-01

3. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial;Nature Communications;2023-10-24

4. Cancer of unknown primary—The new ESMO guidelines;best practice onkologie;2023-05-22

5. Cancer of unknown primary (CUP) – lokal begrenzt, oligometastatisch und im Kopf-Hals-Bereich;Die Radiologie;2023-03-21